SCHEMBL25694936

SCHEMBL25694936

CCCC(=O)c1nc(C)n(-c2nc(Cl)ncc2F)n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ KMT2A Q03164 1/20 0.37
▸ MAPT P10636 3/20 0.36
▸ RECQL P46063 1/20 0.34
▸ ALDH1A1 P00352 2/20 0.34
▸ ABL1 P00519 2/20 0.33
▸ BCR P11274 2/20 0.33
▸ HTT P42858 3/20 0.33
▸ JMJD6 Q6NYC1 1/20 0.32
▸ RPS6KA5 O75582 1/20 0.32
▸ LMNA P02545 2/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ CASP1 P29466 1/20 0.31
▸ CASP7 P55210 1/20 0.31
▸ L3MBTL1 Q9Y468 2/20 0.31
▸ KDM4E B2RXH2 1/20 0.31
▸ HCRTR1 O43613 1/20 0.31
▸ HCRTR2 O43614 1/20 0.31
▸ HPGD P15428 1/20 0.30
▸ RAB9A P51151 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24054370 0.83 KMT2A (0.56) SMN1; SMN2KMT2AMAPTRECQLALDH1A1
SCHEMBL30166311 0.83 KMT2A (0.56) SMN1; SMN2KMT2AMAPTRECQLALDH1A1
SCHEMBL24054153 0.75 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AMAPTALDH1A1ABL1
SCHEMBL25695023 0.67 KMT2A (0.45) SMN1; SMN2KMT2AMAPTALDH1A1HTT
SCHEMBL30166321 0.66 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AMAPTALDH1A1ABL1
SCHEMBL24054006 0.66 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AMAPTALDH1A1ABL1
SCHEMBL25695425 0.65 SMN1; SMN2 (0.43) SMN1; SMN2KMT2AMAPTALDH1A1LMNA
SCHEMBL16543698 0.65 JUN (0.49) SMN1; SMN2RECQLALDH1A1KDM4EHPGD
SCHEMBL25281989 0.64 ALDH1A1 (0.40) SMN1; SMN2KMT2AMAPTALDH1A1HTT
SCHEMBL31205699 0.64 RPS6KA5 (0.52) SMN1; SMN2KMT2AMAPTALDH1A1RPS6KA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203019-A1 Piperazine Cyclic Ureas SIRONAX (BEIJING) CO., LTD. (CN) 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203019-A1 Piperazine Cyclic Ureas RIPK1, RIPK3, RIPK4 SMN1; SMN2 2977/4885KMT2A 4588/4885MAPT 2881/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback